Playing from staycurrentmd
12 views 0 likes

StayCurrentMD

GCMD Space · View profile →

Updated Favorable histology Wilms tumor risk stratification: Rationale for future Children’s Oncology Group clinical trials

Video Published 2026-04-17

Timestops (3)

0:00
Risk stratification for Wilm's tumor has evolved many times …
Risk stratification for Wilm's tumor has evolved many times over the years, so let's catch up. I'm Jill Knera, the Stay …
0:21
Includes biological and clinical features that were not in t…
Includes biological and clinical features that were not in the first generation risk stratification. It also changes som…
0:43
They also modified how histology and age are used to stratif…
They also modified how histology and age are used to stratify certain patients. Keep an eye out for more changes in the …

Topic Overview

A 53-second update on the Children's Oncology Group's revised risk stratification for favorable histology Wilms tumor, published in Nature in June 2025. The new model incorporates biological markers—loss of heterozygosity at 11P15, 1Q gain, and lymph node involvement—while removing tumor nephrectomy weight and modifying the use of histology and age. The speaker signals that further refinements are expected as ongoing COG trials report results.

Key Takeaways

  • COG now incorporates LOH at 11p15, 1q gain, and lymph node status into favorable histology Wilms tumor risk stratification. (0:32)
  • Tumor nephrectomy weight has been removed from the updated Wilms tumor risk model published in Nature June 2025. (0:09)
  • The new model modifies how histology and age stratify patients, moving beyond first-generation clinical features alone. (0:19)

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

  • Jill Knera — host

Chapters

  • 0:00Updated Wilms Tumor Risk Stratification — Introduction to the Children's Oncology Group's updated risk stratification model for favorable histology Wilms tumor, highlighting new biological markers and removed clinical features.

Key claims

  • 0:00Risk stratification for Wilms tumor has evolved many times over the years. — Jill Knera
  • 0:09The Children's Oncology Group published updated risk stratification for patients with favorable histology Wilms tumor in Nature in June 2025. — Jill Knera
  • 0:19The new risk stratification model includes biological and clinical features that were not in the first generation risk stratification. — Jill Knera
  • 0:27The new model changes some of the older features or gets rid of them altogether. — Jill Knera
  • 0:32Factors being added are loss of heterozygosity of 11P15, 1Q gain, and lymph node involvement. — Jill Knera
  • 0:41Tumor nephrectomy weight is no longer included in the risk stratification. — Jill Knera
  • 0:43The model modified how histology and age are used to stratify certain patients. — Jill Knera
  • 0:48More changes are expected in the future as ongoing COG trials produce more results. — Jill Knera

Open questions

  • What specific changes to histology and age stratification criteria were implemented in the new model?
  • What are the anticipated changes from ongoing COG trials?
This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.

Keywords

Wilms tumor favorable histology Wilms tumor nephrectomy Children's Oncology Group

Hashtags

#WilmsTumor #PediatricOncology #RiskStratification #ChildrensOncologyGroup #COGTrials

Transcript

Comments

Loading comments…